C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II
2015
C.E.R.A. (continuous erythropoietin
receptor activator, pegilated-rHuEPO s) corrects and maintains
stable hemoglobin levels in once-monthly administration in
chronic kidney disease (CKD) patients. The aim of this study was
to evaluate the management of anemia with C.E.R.A. in CKD
patients not on dialysis in the clinical setting.
Methods:
Two
hundred seventy two anemic CKD patients not on dialysis treated
with C.E.R.A. were included in this retrospective, observational,
multicentric study during 2010. Demographical characteristics,
analytical parameters concerning anemia, treatment data and
iron status were recorded.
Results:
C.E.R.A. achieved a good
control of anemia in both naive patients (mean Hemoglobin
11.6g/dL) and patients converted from a previous ESA (mean
Hemoglobin 11.7g/dL). Most naive patients received C.E.R.A.
once monthly during the correction phase and required a low
monthly dose (median dose 75µg/month). The same median
dose was required in patients converted from a previous
ESA, and it was lower than recommended in the Summary of
Product Characteristics (SPC). Iron status was adequate in 75%
of anemic CKD patients, but only 50% of anemic patients with
iron deficiency received iron supplementation.
Conclusions:
C.E.R.A. corrects and maintains stable hemoglobin levels in
anemic CKD patients not on dialysis, requiring conversion doses
lower than those recommended by the SPC, and achieving
target hemoglobin levels with once-monthly dosing frequency
both in naive and converted patients
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
24
References
2
Citations
NaN
KQI